OR WAIT null SECS
Novo Nordisk has revealed the findings from an exploratory analysis of Phase IIIa clinical development program, demonstrating improved glycemic control with oral semaglutide.
Novo Nordisk, in a Sep. 17, 2019 press release, has revealed the findings from an exploratory analysis of Phase IIIa clinical development program, which demonstrate an improvement in glycemic control in type-2 diabetic patients after treatment with oral semaglutide.
According to the analysis data, patients administered with 7 mg and 14 mg of oral semaglutide experienced greater reductions in HbA1cversus the other comparators in the PIONEER trials. The analysis included data from 5657 patients, who had taken part in PIONEER trials 1–5, 7, and 8. Patient groupings for the analysis were determined using baseline HbA1c.
“People with type 2 diabetes have individual treatment goals related to glycemic control,” said Juris Meier, professor of medicine and head of the division of diabetology and GI endocrinology at the St. Josef-Hospital of the Ruhr-University of Bochum, Germany, in the press release. “The findings from this analysis are particularly meaningful as they show that oral semaglutide improves glycemic control in a wide spectrum of people with type 2 diabetes.”
“This analysis reinforces the findings seen throughout the PIONEER trial program, demonstrating oral semaglutide’s efficacy in HbA1creductions compared to commonly used type 2 diabetes treatments,” added Mads Krogsgaard Thomsen, executive vice-president and chief science officer of Novo Nordisk. “If approved, oral semaglutide will become the first and only oral GLP-1 receptor agonist with the potential to help people with uncontrolled type 2 diabetes better manage their condition.”
Source: Novo Nordisk